Previous 10 | Next 10 |
2023-09-01 10:00:10 ET More on Health Care Select Sector SPDR Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare ( XLV ) Tech Ruled The First Half Of 2023, The Industry You Need To Watch In The Second Half XLV Vs. VHT: A Head-To-Head Healthcare ETF C...
2023-08-31 17:19:31 ET Gainers: Nutanix ( NTNX ) +13% . Intuitive Machines ( LUNR ) +9% . NGM Biopharmaceuticals ( NGM ) +7% . Vaxxinity ( VAXX ) +5% . NANO-X IMAGING ( NNOX ) +5% . Losers: Jet ( JTAI ) -4% . ...
2023-08-14 13:19:20 ET Despite recent setbacks, drugmakers are still forging ahead in their quest to develop effective treatments for non-alcoholic steatohepatitis, or NASH, a growing public health concern that could represent a roughly $108B global market opportunity by 2030. According...
2023-08-04 17:35:56 ET Gainers: Atara Biotherapeutics ( ATRA ) +5% . NGM Biopharmaceuticals ( NGM ) +5% . Galera Therapeutics ( GRTX ) +4% . Ovid Therapeutics ( OVID ) +3% . Magnite ( MGNI ) +3% . Losers: Applied Material...
2023-08-03 17:39:54 ET NGM Biopharmaceuticals press release ( NASDAQ: NGM ): Q2 GAAP EPS of -$0.46 in-line. Revenue of $1.42M (-82.9% Y/Y) misses by $1.88M . For further details see: NGM Biopharmaceuticals GAAP EPS of -$0.46 in-line, revenue of $1.42M misses ...
--Announced positive data from Phase 2 investigator-sponsored trial of aldafermin for the treatment of patients with diarrhea-predominant irritable bowel syndrome (IBS-D) and bile acid malabsorption (BAM)-- --Announced topline positive data from Phase 2b ALPINE 4 trial of aldafermin; stud...
2023-06-27 13:03:37 ET Biopharmaceutical firms focused on liver diseases trended lower Tuesday after pharma giant Eli Lilly ( NYSE: LLY ) announced data highlighting the potential of its weight loss candidate retatrutide in obese patients with excess liver fat. The condition kno...
2023-05-29 15:00:00 ET The Institute for Clinical and Economic Review (ICER), the influential U.S. drug pricing watchdog, has warned about the affordability of two medications currently undergoing studies for liver disease, nonalcoholic steatohepatitis (NASH). Issuing a so-called access...
Aldafermin demonstrated statistically significant reductions in serum 7αC4 (a marker of bile acid synthesis) and fecal bile acids versus placebo in patients with idiopathic BAM with IBS-D Around 25-50% of patients with diarrhea-predominant IBS (or IBS-D) have evidence of BAM Find...
2023-05-04 17:27:20 ET NGM Biopharmaceuticals press release ( NASDAQ: NGM ): Q1 GAAP EPS of -$0.58 misses by $0.06 . Revenue of $2.25M (-89.3% Y/Y) misses by $3.89M . Cash, cash equivalents and short-term marketable securities were $231.0 million as of March...
News, Short Squeeze, Breakout and More Instantly...
NGM Biopharmaceuticals Inc. Company Name:
NGM Stock Symbol:
NYSE Market:
NGM Biopharmaceuticals Inc. Website:
SAN FRANCISCO, April 05, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (“NGM Bio”) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that Atlas Neon Parent, Inc. (“Parent”), an...
SOUTH SAN FRANCISCO, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that two abstracts highlighting clinical data from the ongo...
--Enrollment ongoing for patients with microsatellite stability (MSS) colorectal cancer (CRC) in Phase1/2 trial of NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, in combination with KEYTRUDA® (pembrolizumab) with expected completion of enrollment in the second quarter of 202...